摘要
目的观察紫杉醇联合奥沙利铂与紫杉醇联合顺铂（DDP）治疗晚期非小细胞肺癌（NSCLC）的疗效及不良反应。方法80例经病理或细胞学证实的晚期非小细胞肺癌患者按数字随机法分为紫杉醇联合奥沙利铂（T0）组及紫杉醇联合顺铂（TP）组，其中紫杉醇175mg／m2，第1天，T0组加奥沙利铂130mg／m2，第1天；TP组加顺铂25rag／m2，第1～3天。均21天为1个周期。完成3个化疗周期后，按照WHO标准评价化疗疗效和毒性。结果紫杉醇联合顺铂组（TP）：完全缓解0例，部分缓解14例，稳定14例，进展12例，有效率为35％；紫杉醇联合奥沙利铂组（TO）：完全缓解0例，部分缓解12例，稳定16例，进展12例，有效率为30％，两组疗效比较差异无显著性（P〉0．05）。但TO方案显著降低了胃肠道反应、肾功损害及骨髓抑制。结论奥沙利铂与顺铂治疗晚期NSCLC疗效相似，含奥沙利铂的两药方案耐受性较好，更易为患者接受，可以作为治疗晚期NSCLC化疗方案。
Objective To compare the efficacy and toxicity of paclitaxel （TAX） in combination with oxaliplatin （L- OHP） and with cisplatin （DDP） in the treatment of advanced non-small cell lung cancer （NSNLC）. Methods 80 patients with advanced NSCLC diagnosed by pathology or cytology were divided into paclitaxel in combination with oxaliplatin （TO） and paclitaxel in combination with cisplatin （TP）. Paelitaxel 175 rag/m2 on dl, and oxaliplation 130mg/m2 on dl in TO group. Paclitaxel 175 mg/m2 on dl, and cisplatin 25 mg/m2 on dl-3 in TP group. And the chemotherapy was re- peated every 21 days. When completed 2 cycles,evaluated the efficacy and toxicity with standard of WHO. Resnits In TP group, the overall respons rate was 35 ~ （complete remissions0 case, partial remission： 14 case, no change： 14 case, progressive disease： 12 case）. And in TO group, the overall respons rate was 30% （complete remission： 0 case, partial remission.. 12 case, no change： 16 case, progressive disease： 12 case）. The efficacy of two group was similar, but the TO group had the less toxicity of gastrointestinal reaction, renal toxicity and marrow depression. Conclusion The effica- cy is similar for 2 projects in the treatment of advanced NSCLC. But TO project is better tolerance than TP project, and the patients accepted the treatment easily with oxalipatin. So TO project is a good chemotherapy project in the treatment of advanced non-small cell lung cancer.
出处
《西部医学》
2013年第9期1342-1344,共3页
Medical Journal of West China
关键词
紫杉醇
奥沙利铂
顺铂
晚期非小细胞肺癌
化疗
Paclitaxel
Oxalipltin
Cisplatin
Advanced non-small-cell lung cancer
Chemotherapy
